Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (576)	5/9/2000 3:18:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 675

$9.2 million in cash and marketable securities cambneuro.com "During the first quarter of this year we continued to make progress to bring CNS 5161 into a phase II study in chronic pain," stated Harry W. Wilcox, President and CEO of Cambridge NeuroScience, Inc. He continued, "Our plan is to begin a phase II trial of 5161 using an intravenous formulation during the third quarter and advance development of a patch formulation in parallel. We are on target to have preliminary data in pain patients using the i.v. formulation by year end. The goal of this work will be to attract a large pharmaceutical partner for the development of CNS 5161." With a marketcap under 30m, what does that value the rest--10m for 5161, and 10m for the glial growth factor (what is that, a third of potential milestones and no expectation of any royalites--or a 100% discount? And nothing for the old growth factor they licensed away and anything that comes of Allergan. This probably is not far from the catagory of "stupid cheap", but it is an otc.bb so that doesn't help. Maybe CNSI can find some private investors and take the shares away from Wall Street, current marketcap is an insult. Humor: I was buying 3000 shares of Pacific Aerospace today and sure enough, entered CNSI instead of PCTH. Can you say obsessed? ha ha. So that was little ol me buying at 1 5/8ths, whoops--I don't think anybody is going to go after 1 5/8ths when they could have had 1 3/8ths yesterday. Just watch the chart I guess and buy on dips. Hmm, I resemble that remark.